v3.26.1
REVENUES (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]          
Deferred Revenue, Revenue Recognized $ 34.1 $ 34.4 $ 92.4 $ 103.3  
Financing Receivable, Allowance for Credit Loss [Line Items]          
Less: BLS allowance for credit losses 37.2   37.2   $ 36.4
Accounts receivable, net 2,342.4   2,342.4   2,103.8
Gross unbilled services 165.9   165.9   164.0
Less: BLS allowance for credit losses (3.5)   (3.5)   (7.1)
Unbilled services, net   $ 162.4   $ 162.4 156.9
Allowance for Credit Loss, Write Off     (7.4)    
Unbilled Services, Foreign Currency Translation Impact     0.0    
Unbilled Services, Allowance for Credit Loss 3.5   3.5   7.1
Allowance for Credit Loss, Foreign Currency Translation Impact     (0.3)    
Allowance for Credit Loss 40.7   40.7   43.5
Credit Loss Expense (Reversal)     4.9    
Unbilled Services, Credit Loss Expense (Reversal)     0.0    
Accounts Receivable, Credit Loss Expense (Reversal)     4.9    
Unbilled Services, Allowance for Credit Loss, Write Off     3.6    
Accounts Receivable, Allowance for Credit Loss, Writeoff     3.8    
Accounts Receivable, Credit Loss Expense (Reversal)     (0.3)    
Diagnostics          
Financing Receivable, Allowance for Credit Loss [Line Items]          
Accounts Receivable, before Allowance for Credit Loss 1,546.6   1,546.6   1,349.0
Biopharma Laboratory Services          
Financing Receivable, Allowance for Credit Loss [Line Items]          
Accounts Receivable, before Allowance for Credit Loss $ 833.0   $ 833.0   $ 791.2